In a recent study, researchers utilized RiskReveal, a 14-gene expression profile, to pinpoint patients with stage IA-IIA nonsquamous NSCLC who could benefit from adjuvant therapy. Among the 194 evaluable patients, 87 received therapy post-surgery, while 107 were observed. Notably, 55% in each arm had stage IA disease, with well-matched demographics and tumor characteristics. This approach shows promise in tailoring treatment for early-stage NSCLC, potentially improving outcomes and reducing unnecessary chemotherapy exposure.
Read more from ajmc.com
